Anixa reports first 90-day stable disease in Phase 1 ovarian cancer CAR-T trial
ANIX•Anixa Biosciences reported the first case of stable disease lasting three months in its Phase 1 ovarian cancer CAR-T trial, in a patient treated in the highest-dose cohort evaluated so far. No dose-limiting toxicities have been seen to date.
1. Trial update
Anixa reported the first case of stable disease lasting three months in its Phase 1 ovarian cancer CAR-T trial. The patient was treated in the highest-dose cohort evaluated so far. Several treated patients have lived more than a year since therapy, including one beyond two years.
